ARYMO ER Drug Patent Profile
✉ Email this page to a colleague
When do Arymo Er patents expire, and what generic alternatives are available?
Arymo Er is a drug marketed by Zyla and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has twelve patent family members in twelve countries.
The generic ingredient in ARYMO ER is morphine sulfate. There are twenty-three drug master file entries for this compound. Thirty-one suppliers are listed for this compound. Additional details are available on the morphine sulfate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Arymo Er
A generic version of ARYMO ER was approved as morphine sulfate by HOSPIRA on September 30th, 1992.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ARYMO ER?
- What are the global sales for ARYMO ER?
- What is Average Wholesale Price for ARYMO ER?
Summary for ARYMO ER
| International Patents: | 12 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 11 |
| Patent Applications: | 3,492 |
| Drug Prices: | Drug price information for ARYMO ER |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for ARYMO ER |
| DailyMed Link: | ARYMO ER at DailyMed |
Paragraph IV (Patent) Challenges for ARYMO ER
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| ARYMO ER | Extended-release Tablets | morphine sulfate | 15 mg, 30 mg and 60 mg | 208603 | 1 | 2017-12-29 |
US Patents and Regulatory Information for ARYMO ER
ARYMO ER is protected by two US patents.
Patents protecting ARYMO ER
Abuse-deterrent pharmaceutical compositions for controlled release
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
Abuse deterrent pharmaceutical compositions for controlled release
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zyla | ARYMO ER | morphine sulfate | TABLET, EXTENDED RELEASE;ORAL | 208603-001 | Jan 9, 2017 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Zyla | ARYMO ER | morphine sulfate | TABLET, EXTENDED RELEASE;ORAL | 208603-002 | Jan 9, 2017 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Zyla | ARYMO ER | morphine sulfate | TABLET, EXTENDED RELEASE;ORAL | 208603-001 | Jan 9, 2017 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Zyla | ARYMO ER | morphine sulfate | TABLET, EXTENDED RELEASE;ORAL | 208603-002 | Jan 9, 2017 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for ARYMO ER
See the table below for patents covering ARYMO ER around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| New Zealand | 704011 | Abuse deterrent pharmaceutical compositions for controlled release | ⤷ Sign Up |
| China | 104684548 | Abuse deterrent pharmaceutical compositions for controlled release | ⤷ Sign Up |
| South Korea | 20150059167 | 제어된 방출을 위한 남용 제지 약학적 조성물 (ABUSE DETERRENT PHARMACEUTICAL COMPOSITIONS FOR CONTROLLED RELEASE) | ⤷ Sign Up |
| European Patent Office | 2877161 | COMPOSITIONS PHARMACEUTIQUES DE DISSUASION D'ABUS À LIBÉRATION CONTRÔLÉE (ABUSE DETERRENT PHARMACEUTICAL COMPOSITIONS FOR CONTROLLED RELEASE) | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
